Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAM NASDAQ:ESPR NASDAQ:IDYA NASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$22.91+7.7%$19.10$13.52▼$35.25$2.15B2.142.74 million shs3.25 million shsESPREsperion Therapeutics$2.77-0.4%$1.89$0.69▼$3.94$560.51M0.895.84 million shs4.90 million shsIDYAIDEAYA Biosciences$24.72+0.8%$24.08$13.45▼$37.19$2.15B0.121.18 million shs815,159 shsOCULOcular Therapeutix$12.44-0.8%$12.14$5.78▼$13.85$2.18B1.52.13 million shs2.52 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics+7.66%+12.52%+28.56%+34.84%-10.58%ESPREsperion Therapeutics-0.36%+9.06%+35.12%+151.82%+57.39%IDYAIDEAYA Biosciences+0.77%-0.08%+1.60%+13.08%-32.88%OCULOcular Therapeutix-0.80%-2.51%-1.43%+49.34%+39.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$22.91+7.7%$19.10$13.52▼$35.25$2.15B2.142.74 million shs3.25 million shsESPREsperion Therapeutics$2.77-0.4%$1.89$0.69▼$3.94$560.51M0.895.84 million shs4.90 million shsIDYAIDEAYA Biosciences$24.72+0.8%$24.08$13.45▼$37.19$2.15B0.121.18 million shs815,159 shsOCULOcular Therapeutix$12.44-0.8%$12.14$5.78▼$13.85$2.18B1.52.13 million shs2.52 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics+7.66%+12.52%+28.56%+34.84%-10.58%ESPREsperion Therapeutics-0.36%+9.06%+35.12%+151.82%+57.39%IDYAIDEAYA Biosciences+0.77%-0.08%+1.60%+13.08%-32.88%OCULOcular Therapeutix-0.80%-2.51%-1.43%+49.34%+39.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 3.08Buy$46.40102.53% UpsideESPREsperion Therapeutics 2.80Moderate Buy$7.00152.71% UpsideIDYAIDEAYA Biosciences 2.81Moderate Buy$42.8573.33% UpsideOCULOcular Therapeutix 3.00Buy$17.8343.35% UpsideCurrent Analyst Ratings BreakdownLatest ESPR, OCUL, BEAM, and IDYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025BEAMBeam TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.009/15/2025OCULOcular TherapeutixChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.009/12/2025IDYAIDEAYA BiosciencesMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$43.00 ➝ $44.009/9/2025IDYAIDEAYA BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/9/2025IDYAIDEAYA BiosciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $38.009/9/2025IDYAIDEAYA BiosciencesStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$45.009/9/2025IDYAIDEAYA BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/8/2025IDYAIDEAYA BiosciencesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$36.009/4/2025IDYAIDEAYA BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Outperform9/4/2025IDYAIDEAYA BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$41.009/4/2025IDYAIDEAYA BiosciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$40.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$63.52M36.49N/AN/A$8.86 per share2.59ESPREsperion Therapeutics$332.31M1.68$0.02 per share115.71($1.97) per share-1.41IDYAIDEAYA Biosciences$7M309.49N/AN/A$12.25 per share2.02OCULOcular Therapeutix$63.72M33.97N/AN/A$2.01 per share6.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$376.74M-$4.50N/AN/AN/A-661.31%-43.15%-31.06%11/4/2025 (Estimated)ESPREsperion Therapeutics-$51.74M-$0.49N/AN/A62.44-35.84%-0.91%-28.41%11/6/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.79N/AN/AN/AN/A-31.42%-29.45%11/3/2025 (Estimated)OCULOcular Therapeutix-$193.51M-$1.28N/AN/AN/A-382.51%-71.92%-49.36%11/13/2025 (Estimated)Latest ESPR, OCUL, BEAM, and IDYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025BEAMBeam Therapeutics-$1.04-$1.00+$0.04-$1.00$13.29 million$8.47 million8/5/2025Q2 2025ESPREsperion Therapeutics-$0.17-$0.02+$0.15-$0.02$62.55 million$82.39 million8/5/2025Q2 2025IDYAIDEAYA Biosciences-$0.85-$0.88-$0.03-$0.88$3.48 million$6.00 million8/5/2025Q2 2025OCULOcular Therapeutix-$0.35-$0.39-$0.04-$0.39$13.12 million$13.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam TherapeuticsN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam TherapeuticsN/A6.756.75ESPREsperion TherapeuticsN/A1.150.76IDYAIDEAYA BiosciencesN/A12.3912.39OCULOcular Therapeutix0.2310.1010.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%ESPREsperion Therapeutics47.39%IDYAIDEAYA Biosciences98.29%OCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics3.50%ESPREsperion Therapeutics1.70%IDYAIDEAYA Biosciences2.50%OCULOcular Therapeutix2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510101.16 million97.62 millionOptionableESPREsperion Therapeutics200201.62 million198.20 millionOptionableIDYAIDEAYA Biosciences8087.64 million85.45 millionOptionableOCULOcular Therapeutix230173.99 million169.99 millionOptionableESPR, OCUL, BEAM, and IDYA HeadlinesRecent News About These CompaniesChardan Capital Initiates Coverage on Ocular Therapeutix (NASDAQ:OCUL)September 16 at 8:08 AM | marketbeat.comChardan Capital Initiates Coverage of Ocular Therapeutix (OCUL) with Buy RecommendationSeptember 16 at 2:15 AM | msn.comOcular Therapeutix initiated with a Buy at ChardanSeptember 15 at 10:41 AM | msn.comWoodline Partners LP Trims Position in Ocular Therapeutix, Inc. $OCULSeptember 15 at 4:00 AM | marketbeat.comOcular Therapeutix: A Biotech Contender Balancing Promise and Financial RealitySeptember 14 at 2:02 AM | aktiencheck.deA137,871 Shares in Ocular Therapeutix, Inc. $OCUL Acquired by Cubist Systematic Strategies LLCSeptember 10, 2025 | marketbeat.comPolar Asset Management Partners Inc. Lowers Stake in Ocular Therapeutix, Inc. $OCULSeptember 9, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives $17.20 Consensus Price Target from BrokeragesSeptember 9, 2025 | americanbankingnews.comOcular Therapeutix, Inc. (OCUL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 8, 2025 | seekingalpha.comOcular Therapeutix™ to Host Investor Day on September 30, 2025September 8, 2025 | markets.businessinsider.comOcular Therapeutix, Inc. $OCUL Shares Sold by Northern Trust CorpSeptember 8, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of "Buy" from BrokeragesSeptember 8, 2025 | marketbeat.comOcular Therapeutix: A High-Stakes Bet On Becoming The New Standard Of CareSeptember 7, 2025 | seekingalpha.comOcular Therapeutix gains amid takeover speculationSeptember 6, 2025 | msn.comAdage Capital Partners GP L.L.C. Raises Holdings in Ocular Therapeutix, Inc. $OCULSeptember 6, 2025 | marketbeat.comPanagora Asset Management Inc. Cuts Position in Ocular Therapeutix, Inc. $OCULSeptember 6, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Reaches New 1-Year High - Here's WhySeptember 5, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Insider Donald Notman Sells 1,066 SharesSeptember 5, 2025 | insidertrades.comLooking At Ocular Therapeutix's Recent Unusual Options ActivitySeptember 4, 2025 | benzinga.comParadigm Biocapital Advisors LP Makes New Investment in Ocular Therapeutix, Inc. $OCULSeptember 2, 2025 | marketbeat.com414,104 Shares in Ocular Therapeutix, Inc. $OCUL Purchased by Nuveen LLCAugust 31, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeESPR, OCUL, BEAM, and IDYA Company DescriptionsBeam Therapeutics NASDAQ:BEAM$22.91 +1.63 (+7.66%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$22.84 -0.07 (-0.28%) As of 09/16/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Esperion Therapeutics NASDAQ:ESPR$2.77 -0.01 (-0.36%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$2.78 +0.01 (+0.36%) As of 09/16/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.IDEAYA Biosciences NASDAQ:IDYA$24.72 +0.19 (+0.77%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$24.72 0.00 (-0.02%) As of 09/16/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Ocular Therapeutix NASDAQ:OCUL$12.44 -0.10 (-0.80%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$12.56 +0.13 (+1.00%) As of 09/16/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
